Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
|
By LabMedica International staff writers Posted on 22 Jan 2024 |
|
Fujirebio Holdings (Tokyo, Japan) and Agappe Diagnostics (Kochi, India) have entered into a Contract Development and Manufacturing Organization (CDMO) partnership for manufacturing cartridge-based CLIA system reagents for the Mispa i60 and Mispa i121 immunology analyzers. These analyzers and reagents will be sold under Agappe’s brand, making it the first Indian local company with a complete chemiluminescence solution made from reagents produced domestically.
The companies have outlined plans to launch these products in June 2024. Significant milestones have already been achieved, including the finalization of a supply and license agreement in March 2023. Agappe is currently in the advanced stages of technical transfer from Fujirebio, which will enable the Indian company to manufacture chemiluminescence reagents using Fujirebio’s technology and materials. The collaboration is set to make a substantial impact, with phased launches planned for a complete range of over 30 parameters, spanning various medical segments such as oncology, thyroid, cardiac, fertility, and infectious diseases. Additionally, Fujirebio’s groundbreaking biomarkers for Alzheimer’s and other neurodegenerative diseases are also included in this project.
Under this agreement, Fujirebio will be responsible for supplying the Mispa i60 and i121 analyzers and the raw materials for the reagents. Agappe, on the other hand, will focus on developing and manufacturing reagents specifically tailored for these instruments, ensuring compliance with all regulatory requirements. This partnership is based on a shared vision of leveraging each company’s unique strengths to not only foster growth in India's immunoassay market but also to significantly contribute to the advancement and enhancement of immunoassay solutions within the Indian healthcare sector.
“This partnership with Agappe, the renowned market leader with years of success in clinical chemistry, hematology, immunochemistry, and point of care in India, will accelerate our CDMO strategy in one of the most important and fastest growing countries in the world,” said Goki Ishikawa, President and CEO, Fujirebio Holdings, Inc. “We share a vision that, combining mutually complementary strengths of both companies, Agappe together with Fujirebio can deliver high-quality chemiluminescence solutions with cost competitiveness and contribute to the healthcare advancement in India.”
“Leveraging the combined strengths of Agappe and Fujirebio, we are committed to introducing high quality, affordable, and unique chemiluminescence solutions for the country,” added Thomas John, Managing Director, Agappe Diagnostics, Ltd. “This partnership symbolizes our dedication to innovation and our pledge to make advanced diagnostic products more accessible to every Indian. We are poised to set new benchmarks in the industry, emphasizing our joint endeavor to enhance healthcare standards across our nation."
Related Links:
Fujirebio Holdings
Agappe Diagnostics
Latest Industry News
- Hospital Partnership Advances Clinical Validation of Portable Diagnostic Technology
- Diazyme Expands Chemistry Testing Portfolio With Alfa Wassermann Acquisition
- Global TB Summit Connects Diagnostic Testing With Prevention and Clinical Care
- Agilent Acquisition of Proscia to Advance AI-Enabled Digital Pathology Workflows
- Digital Pathology Collaboration Expands Laboratory Access to AI-Driven Diagnostics
- Multi-Cancer Screening Blood Test Gains FDA Breakthrough Designation
- European Approval Expands Liquid Biopsy Use in Advanced Breast Cancer Testing
- Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China
- Collaboration Advances Automated Benchtop Platform for Routine Blood Testing
- Expanded Partnership Supports AI Biomarker Validation and Clinical Trial Deployment
- Multi-Cancer Early Detection Test Wins FDA Panel Backing for Approval
- Mayo Clinic Laboratories and Pathology Asia Expand Genomic Testing Across Asia-Pacific
- Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection
- New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing
- Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing
- Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals
Channels
Clinical Chemistry
view channel
Multimodal Clinical Data Models Predict Cachexia Risk Across Cancers
Cancer cachexia is a severe wasting syndrome that affects roughly half of patients with cancer and cannot be reversed simply by increasing food intake. It can reduce treatment tolerance, impair quality... Read more
Study Evaluates Alzheimer’s Blood Biomarker Across Racial and Ethnic Groups
Alzheimer’s disease trials increasingly depend on identifying cognitively unimpaired people who already have elevated brain amyloid. Blood biomarkers may help reduce reliance on positron emission tomography... Read more
Molecular Diagnostics
view channel
AI Tool Classifies Pathogenic Variants in Severe Childhood Epilepsy
Developmental and epileptic encephalopathies are rare neurodevelopmental disorders characterized by early-life seizures and significant developmental delays. Genetic testing can identify variants associated... Read more
Noninvasive Cervical Test Detects Endometrial Cancer for Triage
Endometrial cancer is rising in incidence and mortality in the United States. The disease has no population screening program or FDA-cleared noninvasive test for early identification, and evaluation can... Read more
Hematology
view channel
New Myelofibrosis Guidelines Recommend Expanded Genetic Testing at Diagnosis
Myelofibrosis is a rare, life-threatening blood cancer affecting up to six per 100,000 people. The disease causes scarring in the bone marrow, limiting the production of healthy blood cells and potentially... Read more
Handheld Point-of-Care Test Aims to Enable Rapid Coagulation Assessment in Trauma
Severe blood loss and inadequate tissue oxygenation are leading causes of preventable death after traumatic injury. Blood products are essential in trauma care, but cold-chain storage, short shelf life,... Read more
Immunology
view channel
FDA Approval Adds Automated Testing Option for Parvovirus B19 Serology
Human Parvovirus B19 is a highly contagious erythrovirus transmitted mainly through respiratory droplets and close contact. Diagnosis relies on IgM antibodies to detect active infection and IgG antibodies... Read more
Blood-Based Immune Aging Map Could Help Spot Disease Risk Earlier
Chronological age does not always reflect immune health or future disease risk. Two adults of the same age can have immune systems that age very differently, with some remaining resilient while others... Read more
Microbiology
view channel
Rapid Host-Response Test Aims to Predict Corticosteroid Benefit in Sepsis
Sepsis and severe infections are difficult to treat because patients with similar clinical presentations may have very different underlying immune responses. Corticosteroids are commonly used in severe... Read more
Oral and Lung Microbiome Changes Linked to Severe Long Covid Symptoms
Long Covid can involve persistent respiratory, cognitive, and gastrointestinal symptoms after acute infection, creating a difficult diagnostic and management challenge. Because COVID-19 initially affects... Read more
Pathology
view channel
Molecular Testing Refines Barrett’s Esophagus Progression Risk Beyond Biopsy Findings
Barrett’s esophagus is a precancerous condition associated with increased risk of esophageal adenocarcinoma. Routine endoscopic biopsy findings guide surveillance and therapy, but histopathology may not... Read more
Updated Digital Pathology Platform Expands AI Integration for Cancer Diagnosis
Digital pathology is reshaping how laboratories manage case review, image analysis, and collaboration. As diagnostic workflows become more complex, pathology teams need platforms that can support digital... Read more
Technology
view channel
Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
